Home MarketStrides Shasun Ltd.

Strides Shasun Ltd. Stock Info: As on 2017-11-17 15:59:53



52 Week Range
Day's Range690.71 - 844.20
Value Traded (in ₹ Cr.) 69.82



Change %
52 Week Range
Day's Range690.03 - 843.37
Value Traded (in ₹ Cr.) 4.59

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 27,848,384.00 31.12%
Mutual Funds/UTI 13,470,250.00 15.05%
FII 30,615,875.00 34.21%
Employee 0.00 0.00%
Public 11,325,984.00 12.66%
Government 0.00 0.00%
Others 5,466,703.00 6.11%

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.41
Basic EPS (Rs.) 19.50
Cash EPS 29.87
BVPerShare Excl 350.93
Operating Revenue 246.62
PBDITPerShare 47.35
Dividend 4.00
NPPerShare 18.03
Current Ratio 2.06
Quick Ratio 1.77
PriceToBV 3.10
Earnings 0.01
PBDIT Margin 19.19
PBT Margin 8.59
NP Margin 7.30
Return On Assets 3.00
Retention Ratios 73.63
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,344.45
Total Expenses 2,129.99
EBITDA 423.02
PBT 189.29
PAT 161.07
Net Income 161.07
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,244.33
Total Expenses 1,082.98
EBITDA 106.21
PBT 108.08
PAT 108.97
Net Income 0.00
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 89.35
Net worth 3,135.41
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 89.35
Net worth 3,135.40
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

532.4 535.15 -0.51

Abbott India Ltd.

4948.2 4866 1.69

Ajanta Pharma Ltd.

1273.4 1229.45 3.57

Albert David Ltd.

292 287.15 1.69

Alembic Ltd.

39.3 39 0.77

Alembic Pharmaceuticals Ltd.

516.1 515.65 0.09

Alkem Laboratories Ltd.

1974.85 1975 -0.01
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

46.45 50.4 -7.84

Aarti Drugs Ltd.

534 533.75 0.05

Aayush Food & Herbs Ltd.

44.6 40.55 9.99

Abbott India Ltd.

4942 4867.5 1.53

ABL Bio-Technologies Ltd.

0.81 0.78 3.85

Addlife Pharma Ltd.

0.46 0 0

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 83.56
Cash from investing activities -1,064.38
Cash from financing activities 1,570.84
Net change in cash 591.96

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
SBI Blue Chip Fund 1.14%
SBI Magnum Midcap Fund 2.82%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.48%
SBI Pharma Fund 7.08%
DSP BlackRock Balanced Fund 1.08%
Reliance Arbitrage Advantage Fund 0.59%

PVR to acquire minority stake in US-based theatre firm iPic

PVR said it will acquire a minority stake in US-based luxury restaurant and theatre company iPic Gold Class Entertainment LLC (iPic) for an undisclosed sum, a move that would give PVR exposure in the cinema exhibition market of the US, reported PTI. iPic owns and operates 16 luxury theatres and 121 screens across 10 states in the United States. The Board of Directors approved the proposed investment and strategic partnership between PVR and iPic, PVR Ltd said in a regulatory filing. The completion of investment is subject to relevant corporate and regulatory approvals. Besides, iPic has agreed to appoint PVR Chairman and Managing Director Ajay Bijli to its board of directors after its planned initial public offering that it had announced earlier.

17-11-2017 10:39

ArcelorMittal, Tata Steel evince interest in Bhushan Steel

ArcelorMittal and domestic industry major Tata Steel have evinced interest in Bhushan Steel which is undergoing insolvency proceedings, reported PTI. The development has come at a time when the debt-laden firm, which was referred to NCLT by the RBI under the Insolvency and Bankruptcy Code, has reported narrowing down of its standalone net loss to Rs 467.37 crore during the September quarter from Rs 980.22 crore in the same period a year ago. During the July-September 2017, total income of Bhushan Steel rose 43 per cent to Rs 4,325.60 crore from Rs 3,025.79 crore during the same period a year ago, the company said in a BSE filing. Yes! ArcelorMittal is interested in Bhushan Steel, said a person in the know of the matter and refused to elaborate further. When contacted, a Tata Steel company official said, The company keeps on looking at such opportunities. Last month, Tata Steel and ArcelorMittal had submitted expression of interest (EoI) to acquire debt-laden Essar Steel -- another stressed company undergoing the insolvency proceedings at the National Company Law Tribunal (NCLT). Essar Steel India Ltd, an integrated steel producer with an installed capacity of 10 million tonne per annum (MTPA) is undergoing Corporate Insolvency Resolution Process (CIRP) under the provisions of Insolvency and Bankruptcy Code. According to the information on Bhushan Steel Ltd website, the company is the 3rd largest secondary steel producer in the country with an existing steel production capacity of 5.6 million ton per annum. Both Tata Steel and ArcelorMittal see the proceedings as an opportunity as the two companies are looking to expand their operations in the country.

17-11-2017 10:28

Jaiprakash Associates approves 'cashless exchange' of bonds

Debt-ridden Jaiprakash Associates' finance committee has approved cashless exchange of existing convertible bonds worth USD 150 million due in 2017 with those maturing in 2020-21, reported PTI. Earlier this month, the RBI had approved the proposal. In a BSE filing, Jaiprakash Associates said that the finance committee in its meeting held today has deemed to have opened and closed the cashless exchange of the existing bonds with the bonds... In June, Jaiprakash Associates had said that bondholders agreed to exchange outstanding existing foreign currency convertible bonds (FCCBs) worth USD 150 million. The bonds were issued in September 2012 with maturity in 2017 and a coupon rate of 5.75 per cent. As per the proposal, the bondholders agreed to exchange their current bonds with FCCBs worth USD 38.64 million bearing the same coupon rate with maturity in 2021 and amortising bonds worth USD 81.69 million with coupon rate of 4.76 per cent and maturity in 2020. According to the regulatory filing, Jaiprakash Associates will issue 1,10,400 'Series A' bonds having principle value of USD 350 each carrying a coupon rate of 5.75 per cent per annum with maturity on September 30, 2021. It will also issue 1,10,400 'Series B' bonds having principle value of USD 740 each at a coupon rate of 4.76 per cent per annum and maturity date of September 30, 2020. That apart, the company will pay USD 27.6 million upfront. The finance committee has authorised execution of all transaction document and closing of the transaction would take place on restructuring effective date, which is expected to take place on or before November 30, 2017, on which date the allotment of the bonds and issuance of global certificates would be made, the filing said. Both series of the bonds would be listed on Singapore Stock Exchange Securities Trading Ltd. Jaiprakash Associates, which is the flagship company of the Jaypee group, is selling its assets to repay debt. It is a diversified infrastructure company engaged in segments like engineering, construction and real estate development, cement manufacturing, hospitality and sports management. Jaypee Group firm Jaypee Infratech has been taken over by a National Company Law Tribunal (NCLT)-appointed IRP (Insolvency Resolution Professional) for recovery of bad loans. The group is facing huge protest from home buyers due to significant delays in delivery of projects.

17-11-2017 10:26

Tata Power allots debentures worth Rs 1500 cr

Tata Power has raised Rs 1,500 crore through issuance of unsecured, redeemable and non- convertible debentures worth Rs 1,500 crore on private placement basis, reported PTI. Company alloted unsecured, non-cumulative, redeemable, taxable, listed, rated non-convertible debentures of Rs 1,500 crore on November 16, 2017 on private placement basis, Tata Power said in a BSE filing. According to the statement, the tenure of these 15,000 debentures is seven years.

17-11-2017 10:21

Cipla gets final nod for Generic Pulmicort Respules

Drug maker Cipla on Friday said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Budesonide InhalationSuspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the United States Food and Drug Administration (USFDA) to market a generic version of Astrazeneca’s Pulmicort Respules. “Cipla’s Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL, are AN-rated generic equivalents of Astrazeneca’s Pulmicort Respules and are indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age,” the company said in a filing to the Bombay Stock Exchange. The product is available for shipping immediately, it said. Pulmicort Respules and generic equivalents had US sales of approximately USD 825 Million for the 12-month period ending September 2017, as reported by IMS Health.

17-11-2017 09:09

Strides Shasun L - Financial Result Updates

Strides Shasun Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

31-Oct-2017 06:01 PM

Strides Shasun L - Outcome of Board Meeting

Allotment of Equity Shares to Employees on exercise of ESOPs

31-Oct-2017 05:02 PM

Strides Shasun L - Allotment of ESOP/ESPS

Strides Shasun Limited has informed the Exchange regarding allotment of 5654 Equity Shares under ESOP

31-Oct-2017 04:56 PM

Strides Shasun L - Outcome of Board Meeting

Strides Shasun Limited has informed the Exchange regarding Outcome of Board Meeting held on October 31, 2017.

31-Oct-2017 04:23 PM

Strides Shasun L - Outcome of Board Meeting

Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

31-Oct-2017 04:16 PM

Strides Shasun L - Outcome of Board Meeting

Allotment of Equity Shares to Employees on exercise of ESOPs

31-Oct-2017 05:02 PM

Strides Shasun L - Outcome of Board Meeting

Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

31-Oct-2017 04:16 PM

Strides Shasun L - Outcome of Board Meeting

Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2017

31-Oct-2017 01:56 PM

Corporate Details

About Management

2002 -Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd. -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route. -Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act. -Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary. -Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations. 2003 -Nominates Mr Francis Pinto as the Director on the Board of the company. -Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems. -Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products. -Changes in the Management: Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO. -Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company. -Strides inks MoU with Ribbon SRL for Cephalosporin 2004 -Major Fire occurs in Private Custom Bonded warehouse in Mexico -Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme''. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job. 2005 - Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets. -Strides Arcolab enters into an agreement for private placement issue - Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs -Strides acquires sterile manufacturing facility in Poland 2007 - Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb's Sustiva, which helps in preventing the HIV virus from reproduction. - Strides Arcolab receives 2 more NDA approvals from US-FDA. 2008 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials. 2010 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company. 2011 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite -Strides announces First European Approval for Oncology Product -Strides Arcolab receives US FDA Nod to Commercialize First Liquid -StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem 2012 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile -Strides Arcolab receives US FDA approval for Methotrexate Injection -Strides Arcolab Announces Health Canada Approval For Tobramycin Injection -Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz -Strides collaborates with Gilead Sciences 2013 -Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet. - Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. - Strides announces WHO pre-qualification for Artemether + Lumifantrine . -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology. -Strides Arcolab - Re-branding Biotech Business as ''Stelis''. -Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market. 2014 -- Medicines for Malaria Venture announces collaborations with Cipla and Strides. -Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. - Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. -Strides Arcolab receives US FDA approval for Buspirone Tablets. -Strides Arcolab receives US FDA approval for Calcitriol Softgel. -Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. -Strides Arcolab to acquire Shasun Pharma in all stock deal. 2015 -Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc -Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc, -Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso" -Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug -Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company. -Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia. -Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy -Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited" 2016 -Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson". -Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy". -"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia". -"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya". -"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet". - "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore".

Registered Office

CHENNAI OFFICE: `Batra Centre', 3rd and 4th Floor, 28, Sardar Patel Road, Guindy,

044-43446700,22207500,,      044-22350278,

Registrar Details

Karvy Computershare Private Ltd.